Section 70
Chapter 69,237

Utility of Targeted, Amplicon-Based Deep Sequencing to Detect Resistance to First-Line Tuberculosis Drugs in Botswana

Wang, Q.; Modongo, C.; Allender, C.; Engelthaler, D.M.; Warren, R.M.; Zetola, N.M.; Shin, S.S.

Antimicrobial Agents and ChemoTherapy 63(11)


ISSN/ISBN: 1098-6596
PMID: 31405858
DOI: 10.1128/aac.00982-19
Accession: 069236815

Download citation:  

Multidrug-resistant tuberculosis (TB) is an alarming threat, and targeted deep sequencing (DS) may be an effective method for rapid identification of drug-resistant profiles, including detection of heteroresistance. We evaluated the sensitivity and specificity of targeted DS versus phenotypic drug susceptibility testing (pDST) among patients starting first-line anti-TB therapy in Botswana. Overall, we found high concordance between DS and pDST. Lower sensitivity of DS, which targets established high-confidence resistance variants, was observed for detecting isoniazid resistance among HIV-infected patients.

PDF emailed within 0-6 h: $19.90